MMS Holdings Inc. has been selected by Health Data Research UK as a partner to support the International COVID-19 Data Alliance (ICODA) initiative. MMS was selected from a pool of the world’s clinical research organizations to provide data engineering services to support a globally coordinated, health data-led research response to tackle the COVID-19 pandemic.
ICODA is an open and inclusive global collaboration of life science, philanthropic and research organizations that have come together to harness the power of health data to respond to the COVID-19 pandemic. Uniting data from a broad set of contributors will enable discoveries that will help treat and prevent COVID-19 and coordinate effective data responses to health challenges of the future.
During the pilot phase of the project, MMS will provide flexible service levels based on the capability of each contributor to transform their data to ICODA standards. The MMS biometrics and data science team will provide simple guidance to the full range of data services and data mapping as needed.
After the pilot completes, MMS data scientists will use learnings to develop tools to further enable contributors such as open-source code and training that academic researchers can use to transform their own data. Additionally, later phases of the engagement may include data mapping and incorporation of real-world health data.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.